The FRACTAL registry received financial support from Medtronic Inc. and AstraZeneca. Dr. Reynolds is the recipient of grant K23-HL077171 from the National Heart, Lung, and Blood Institute (NHLBI). Dr. Essebag is the recipient of a Clinician Scientist Award from the Canadian Institutes of Health Research (CIHR).
Healthcare Resource Utilization and Costs Associated with Recurrent Episodes of Atrial Fibrillation: The FRACTAL Registry
Article first published online: 19 APR 2007
Journal of Cardiovascular Electrophysiology
Volume 18, Issue 6, pages 628–633, June 2007
How to Cite
REYNOLDS, M. R., ESSEBAG, V., ZIMETBAUM, P. and COHEN, D. J. (2007), Healthcare Resource Utilization and Costs Associated with Recurrent Episodes of Atrial Fibrillation: The FRACTAL Registry. Journal of Cardiovascular Electrophysiology, 18: 628–633. doi: 10.1111/j.1540-8167.2007.00819.x
Manuscript received 28 November 2006; Revised manuscript received 6 February 2007; Accepted for publication 9 February 2007.
- Issue published online: 19 APR 2007
- Article first published online: 19 APR 2007
- atrial fibrillation;
- drug therapy;
Introduction: Drivers of cost in the atrial fibrillation (AF) population are not fully understood. We sought to characterize the resource utilization and costs of treating new-onset AF, with emphasis on the incremental costs associated with recurrent episodes of AF over time.
Methods and Results: An inception cohort of 973 AF patients was followed at 3–6 month intervals in an observational registry over a mean of 24 ± 9 months. AF therapies, clinical outcomes, and both inpatient and outpatient medical resource utilization were tracked at each follow-up interval. Registry patients were managed primarily with cardioversion and pharmacological therapy. Direct healthcare costs were calculated from a U.S. perspective by multiplying measures of resource utilization by representative price weights. Costs were compared among patients in whom the initial episode of AF became permanent and patients who initially achieved sinus rhythm and had either 0, 1–2, or ≥3 documented recurrences during follow-up. Mean annual costs for these four groups were $2,372, $3,385, $6,331, and $10,312 per patient per year, respectively (P < 0.001 for trend), with the largest variation related to hospital costs. In multivariable analysis controlling for demographic characteristics and baseline cardiac and comorbid conditions, each documented recurrence of AF was found to increase annual healthcare costs by ∼$1,600.
Conclusion: Following initial diagnosis, patients with AF treated with traditional therapies incur $4,000–$5,000 in annual direct healthcare costs. Costs are markedly higher in patients with multiple AF recurrences. These data may be helpful in evaluating the economic impact of new technologies for treating AF.